Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
for Non-small Cell Lung Cancer (NSCLC)
50 locations incl. Chandler
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT07291037·Phase 3·Recruiting